Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has been assigned an average recommendation of “Buy” from the ten research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $39.50.

A number of analysts have recently issued reports on ADMS shares. Piper Jaffray Companies restated an “overweight” rating and set a $30.00 price objective on shares of Adamas Pharmaceuticals in a research report on Friday, September 1st. They noted that the move was a valuation call. BidaskClub cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Adamas Pharmaceuticals in a research report on Sunday, September 17th. Finally, Cowen and Company set a $45.00 price objective on Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th.

Adamas Pharmaceuticals (ADMS) traded down 4.38% during mid-day trading on Wednesday, hitting $20.74. 926,752 shares of the stock were exchanged. Adamas Pharmaceuticals has a one year low of $12.10 and a one year high of $24.18. The company has a 50-day moving average price of $20.71 and a 200-day moving average price of $17.68. The company’s market cap is $466.94 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.12). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million. During the same period in the previous year, the business posted ($0.78) EPS. The firm’s revenue was down 90.9% on a year-over-year basis. On average, analysts predict that Adamas Pharmaceuticals will post ($3.77) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Adamas Pharmaceuticals, Inc. (ADMS) Given Average Rating of “Buy” by Brokerages” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/11/adamas-pharmaceuticals-inc-adms-given-average-rating-of-buy-by-brokerages.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADMS. Tower Research Capital LLC TRC bought a new stake in Adamas Pharmaceuticals in the second quarter valued at $109,000. American International Group Inc. grew its position in Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock valued at $180,000 after acquiring an additional 682 shares during the period. Virtu KCG Holdings LLC bought a new stake in Adamas Pharmaceuticals in the second quarter valued at $184,000. Wells Fargo & Company MN grew its position in Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after acquiring an additional 3,358 shares during the period. Finally, Alps Advisors Inc. grew its position in Adamas Pharmaceuticals by 6.7% in the second quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock valued at $353,000 after acquiring an additional 1,272 shares during the period. Institutional investors and hedge funds own 69.16% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.